Karen C. Wolff - Concepedia

Concepedia

Author

Karen C. Wolff

Genomics Institute of the Novartis Research Foundation

Also Known As

Karen C. Wolff, Karen C. Wolff, Karen Wolff, Stevens, Laura J.

34

Publications

1.6K

Citations

16

H-Index

34

Concepts

All Affiliations

Genomics Institute of the Novartis Research Foundation California Institute for Biomedical Research Scripps Research Institute UC San Diego Health System University of California, Santa Barbara

KC

About

Karen C. Wolff is an author at Genomics Institute of the Novartis Research Foundation specializing in medicine, hiv, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	922
2	Natural Sciences	3	3	522
3	Biochemistry	3	3	522
4	Biomolecular Engineering	3	3	215
5	Engineering	1	1	49

Karen C. Wolff

×

18

Publications

1.6K

Citations

16

H-Index

	Year	Citations
Design, synthesis and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part I Tao Jiang, Kelli Kuhen, Karen C. Wolff, Bioorganic & Medicinal Chemistry Letters Medicinal ChemistryBiochemistryBiological EvaluationsNovel OxindolesMedicine	2006	290
Mutations in an Auxin Receptor Homolog AFB5 and in SGT1b Confer Resistance to Synthetic Picolinate Auxins and Not to 2,4-Dichlorophenoxyacetic Acid or Indole-3-Acetic Acid in Arabidopsis Terence A. Walsh, Roben Neal, Ann Owens Merlo, PLANT PHYSIOLOGY	2006	224
Design, synthesis, and biological evaluations of novel oxindoles as HIV-1 non-nucleoside reverse transcriptase inhibitors. Part 2 Tao Jiang, Kelli Kuhen, Karen C. Wolff, Bioorganic & Medicinal Chemistry Letters Medicinal ChemistryBiochemistryBiological EvaluationsNovel OxindolesMedicine	2006	197
Drug repurposing screens identify chemical entities for the development of COVID-19 interventions Malina A. Bakowski, Nathan Beutler, Karen C. Wolff, Nature Communications	2021	127
Antiviral drug screen identifies DNA-damage response inhibitor as potent blocker of SARS-CoV-2 replication Gustavo Garcia, Arun Sharma, Arunachalam Ramaiah, Cell Reports	2021	117
Identification of broad-spectrum antiviral compounds and assessment of the druggability of their target for efficacy against respiratory syncytial virus (RSV) Aurelio Bonavia, Michael Franti, Erin P. Keaney, Proceedings of the National Academy of Sciences Novel Therapeutic InterventionsMedicinal ChemistryRespiratory Syncytial VirusViral DiseaseSynthetic Virology	2011	94
Design, synthesis, and biological evaluations of novel quinolones as HIV-1 non-nucleoside reverse transcriptase inhibitors David Ellis, Kelli Kuhen, Beth Anaclerio, Bioorganic & Medicinal Chemistry Letters Biological EvaluationsMedicineNovel QuinolonesHuman RetrovirusAntiviral Drug Development	2006	86
RNA adenosine deaminase ADAR1 deficiency leads to increased activation of protein kinase PKR and reduced vesicular stomatitis virus growth following interferon treatment Zhiqun Li, Karen C. Wolff, Charles E. Samuel Virology Protein Kinase PkrViral ReplicationMolecular VirologyPathogenesisImmunology	2009	80
“UnPAKing” Human Immunodeficiency Virus (HIV) Replication: Using Small Interfering RNA Screening To Identify Novel Cofactors and Elucidate the Role of Group I PAKs in HIV Infection Deborah G. Nguyen, Karen C. Wolff, Hong Yin, Journal of Virology	2005	73
Vaccinia Virus E3L Interferon Resistance Protein Inhibits the Interferon-Induced Adenosine Deaminase A-to-I Editing Activity Yong Liu, Karen C. Wolff, Bertram L. Jacobs, Virology Viral ReplicationMolecular VirologyPathogenesisImmunologyAntiviral Response	2001	64

Page 1